Roberto Piva
Overview
Explore the profile of Roberto Piva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Percivalle N, Bassila J, Piccinini A, Cumerlato M, Porro M, Trouki C, et al.
ACS Appl Mater Interfaces
. 2025 Feb;
17(7):10432-10445.
PMID: 39930563
While recent advances in nanotechnology offer significant possibilities for improving the development of targeted drug delivery systems (DDSs), the design of efficient nanocarriers remains challenging due to the complex interactions...
2.
Vujovic T, Paradzik T, Babic Brcic S, Piva R
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858100
Algae are a rich source of bioactive compounds that have a wide range of beneficial effects on human health and can show significant potential in the treatment of hematological malignancies...
3.
Piva R, Gharari N, Labrador M, Mader S
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409901
The metabolic reprogramming characteristic of cancer cells, including the Warburg effect, has long been recognized as a hallmark of malignancy. This commentary explores three recent investigations focusing on the role...
4.
Puccio N, Manzotti G, Mereu E, Torricelli F, Ronchetti D, Cumerlato M, et al.
Haematologica
. 2024 Jul;
109(12):4040-4055.
PMID: 38988264
Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells within the bone marrow. It is characterized by a highly heterogeneous clinical and molecular...
5.
Bandini C, Mereu E, Paradzik T, Labrador M, Maccagno M, Cumerlato M, et al.
Exp Hematol Oncol
. 2023 Aug;
12(1):71.
PMID: 37563685
Background: Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of...
6.
Mereu E, Abbo D, Paradzik T, Cumerlato M, Bandini C, Labrador M, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190128
Proteasome inhibitors (PIs) are extensively used for the therapy of multiple myeloma. However, patients continuously relapse or are intrinsically resistant to this class of drugs. In addition, adverse toxic effects...
7.
Bottino P, Zanotto E, Sidoti F, Pastrone L, Piva R, Mereu E, et al.
Microorganisms
. 2023 Feb;
11(2).
PMID: 36838500
The COVID-19 pandemic represented a challenge for health-care systems, and a major bottleneck in SARS-CoV-2 diagnosis was the unavailability of extraction reagents. To overcome this limitation, we performed a comparative...
8.
Taiana E, Bandini C, Favasuli V, Ronchetti D, Silvestris I, Puccio N, et al.
Haematologica
. 2022 Sep;
108(1):219-233.
PMID: 36073514
Long non-coding RNA NEAT1 is the core structural component of the nuclear paraspeckle (PS) organelles and it has been found to be deregulated in multiple myeloma (MM) patients. Experimental evidence...
9.
Zorzan E, Elgendy R, Guerra G, Da Ros S, Gelain M, Bonsembiante F, et al.
Int J Mol Sci
. 2022 Apr;
23(7).
PMID: 35409379
Gene expression is controlled by epigenetic deregulation, a hallmark of cancer. The DNA methylome of canine diffuse large B-cell lymphoma (cDLBCL), the most frequent malignancy of B-lymphocytes in dog, has...
10.
Taiana E, Gallo Cantafio M, Favasuli V, Bandini C, Viglietto G, Piva R, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33924959
Multiple myeloma (MM) is a complex hematological malignancy characterized by abnormal proliferation of malignant plasma cells (PCs) within a permissive bone marrow microenvironment. The pathogenesis of MM is unequivocally linked...